These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34309900)

  • 1. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.
    Prevete E; Kuypers KPC; Theunissen EL; Corazza O; Bersani G; Ramaekers JG
    Hum Psychopharmacol; 2022 Jan; 37(1):e2805. PubMed ID: 34309900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
    Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kratom use and mental health: A systematic review.
    Swogger MT; Walsh Z
    Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of urinary protein profile in regular kratom (
    Jasim RK; Hassan Z; Singh D; Boyer E; Gam LH
    J Addict Dis; 2022; 40(2):235-246. PubMed ID: 34747343
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature.
    Stanciu C; Ahmed S; Gnanasegaram S; Gibson S; Penders T; Grundmann O; McCurdy C
    Am J Drug Alcohol Abuse; 2022 Sep; 48(5):509-528. PubMed ID: 36001875
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
    Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
    J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Pharmacology and Legal Status of Kratom.
    Prozialeck WC
    J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.
    Harun N; Kamaruzaman NA; Mohamed Sofian Z; Hassan Z
    Neurosci Lett; 2022 Mar; 773():136500. PubMed ID: 35114335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of deaths associated with kratom use.
    Corkery JM; Streete P; Claridge H; Goodair C; Papanti D; Orsolini L; Schifano F; Sikka K; Körber S; Hendricks A
    J Psychopharmacol; 2019 Sep; 33(9):1102-1123. PubMed ID: 31429622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.
    Hill K; Gibson S; Grundmann O; Smith KE; Ballard J; Stanciu CN
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):21. PubMed ID: 37041624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
    Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
    J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature.
    Bin Abdullah MFIL
    Curr Drug Targets; 2020; 21(15):1566-1579. PubMed ID: 32682371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Kratom (
    Prevete E; Kuypers KPC; Theunissen EL; Esposito G; Ramaekers JG; Pasquini M; Corazza O
    Curr Addict Rep; 2023; 10(2):317-334. PubMed ID: 37266188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic and clinical assessment of kratom.
    White CM
    Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (
    Leong Bin Abdullah MFI; Singh D
    Front Pharmacol; 2021; 12():726003. PubMed ID: 34646135
    [No Abstract]   [Full Text] [Related]  

  • 20. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
    Hassan Z; Muzaimi M; Navaratnam V; Yusoff NH; Suhaimi FW; Vadivelu R; Vicknasingam BK; Amato D; von Hörsten S; Ismail NI; Jayabalan N; Hazim AI; Mansor SM; Müller CP
    Neurosci Biobehav Rev; 2013 Feb; 37(2):138-51. PubMed ID: 23206666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.